乐观
$3.63
情景价格
$1.190
-0.179 (-15.00%)收盘时
IM Cannabis Corp. is an international cannabis company that provides cannabis products to medical patients in Israel and Germany. The Company's ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of its products throughout the entire value chain. In Germany, the Company’s ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. The Company's brands include The Craft Collection, The Top-Shelf Collection, The Signature Collection, The Full Spectrum Extracts, Roma, The WAGNERS, BLKMKT, LOT420, The PICO collection, and Flower.
IM Cannabis Corp. is not a good buy right now due to its significant financial struggles and negative market sentiment. The stock has dropped 96.89% year-to-date, and the current RSI is at 27.00, indicating it is oversold but still under pressure. Additionally, the company reported a net income loss of CAD 4.36 million in Q2 2026, which raises concerns about its profitability and sustainability.
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

IM Cannabis Completes Share Transaction Expected to Boost Shareholders' Equity by C$3 Million

IM Cannabis Completes Share Transaction, Expected C$3 Million Increase in Shareholders' Equity

IM Cannabis Corp. Regains Nasdaq Compliance

IM Cannabis Corp. Prices Direct Offering Raising $1.31 Million

IM Cannabis Corp. Completes Sale of 655,000 Shares in Direct Offering
IM Cannabis Corp. is an international cannabis company that provides cannabis products to medical patients in Israel and Germany. The Company's ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of its products throughout the entire value chain. In Germany, the Company’s ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. The Company's brands include The Craft Collection, The Top-Shelf Collection, The Signature Collection, The Full Spectrum Extracts, Roma, The WAGNERS, BLKMKT, LOT420, The PICO collection, and Flower. It operates in the Consumer Non-Cyclicals sector (MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS industry).
IM Cannabis Corp. is not a good buy right now due to its significant financial struggles and negative market sentiment. The stock has dropped 96.89% year-to-date, and the current RSI is at 27.00, indicating it is oversold but still under pressure. Additionally, the company reported a net income loss of CAD 4.36 million in Q2 2026, which raises concerns about its profitability and sustainability.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。